ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |
| EMERALD ADVISERS, LLC | 491,689 | $17,528,717 | 0.85% |
| Avoro Capital Advisors LLC | 1,500,000 | $53,475,000 | 0.83% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 387,323 | $13,808,065 | 0.83% |
| Avidity Partners Management LP | 544,000 | $19,393,600 | 0.78% |
| Ikarian Capital, LLC | 174,945 | $6,236,790 | 0.75% |
| AlphaCentric Advisors LLC | 30,000 | $1,069,500 | 0.61% |
| EFG Asset Management (North America) Corp. | 57,921 | $2,065,173 | 0.49% |
| Motley Fool Asset Management LLC | 156,104 | $5,565,108 | 0.45% |
| Motley Fool Wealth Management, LLC | 168,259 | $5,998,607 | 0.35% |
| Sands Capital Management | 2,577,217 | $91,877,786 | 0.31% |
External links
This page lists ULTRAGENYX PHARMACEUTICAL IN's shareholders in Q3 2023. To view ULTRAGENYX PHARMACEUTICAL IN's shareholder history, click here.